Theriva Biologics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results
Theriva Biologics (NYSE American: TOVX) announced a conference call on March 27, 2023, at 8:30 a.m. ET to discuss its financial results for Q4 and the full year ending December 31, 2022, along with corporate updates. The company is focused on developing therapeutics to treat cancer and related diseases, emphasizing its lead candidates: VCN-01, SYN-004, and SYN-020. These candidates target tumor cell death, prevent microbiome damage, and aim to treat gastrointestinal and systemic diseases, respectively. Investors can join the live call or access it later via the company's website.
- Plans to discuss financial results and corporate updates, indicating transparency.
- Focus on developing innovative cancer therapies addressing high unmet needs.
- Lead candidates could significantly impact treatment options for patients.
- No specific financial metrics or guidance were provided in the PR.
ROCKVILLE, Md., March 20, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, March 27, 2023, at 8:30 a.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2022 and provide a corporate update.
Individuals may participate in the live call via telephone by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) and using the conference ID: 13736047. Participants are asked to dial in 15 minutes before the start of the call to register. Investors and the public can access the live and archived webcast of this call via the “News & Media” section of the company’s website, https://www.therivabio.com, under “Events” or by clicking here, up to 90 days after the call.
About Theriva Biologics, Inc.
Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s subsidiary, Theriva Biologics, S.L. (formerly known as VCN Biosciences, S.L.), has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients; and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics' website at www.therivabio.com.
For further information, please contact:
Investor Relations:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
Source: Theriva Biologics, Inc.
FAQ
What is the date of Theriva Biologics' next conference call?
What financial results will Theriva Biologics discuss in their conference call?
What are the lead candidates of Theriva Biologics?
How can investors access the conference call?
